Clinical attempts to disrupt the total TAM population by inhibiting the interactions between colony stimulating factor 1 receptor (CSF1R) with its ligands CSF1 and IL-34 have shown limited efficacy in GBM and other solid tumors [22, 23]. The gene discussed is CSF1R; the disease is glioblastoma.